Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PVLA Palvella Therapeutics

Market Closed 12-12 16:00:00 EST

98.58

+1.80

+1.86%

盘后98.58

+0.000.00%

19:23 EST

High99.40	Low95.86	Vol192.74K
Open97.81	D1 Closing96.78	Amplitude3.66%
Mkt Cap1.17B	Tradable Cap705.68M	Total Shares11.84M
T/O18.80M	T/O Rate2.69%	Tradable Shares7.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":98.58,"timestamp":1765573200000,"preClose":96.78,"halted":0,"volume":192735,"hourTrading":{"tag":"盘后","latestPrice":98.58,"preClose":98.58,"latestTime":"19:23 EST","volume":4184,"amount":412458.77,"timestamp":1765585386013},"delay":0,"floatShares":7158500,"shares":11836490,"eps":-3.529122,"marketStatus":"Market Closed","change":1.8,"latestTime":"12-12 16:00:00 EST","open":97.81,"high":99.4,"low":95.86,"amount":18799537.6521,"amplitude":0.036578,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":96.78,"preHourTrading":{"tag":"盘前","latestPrice":98.24,"preClose":96.78,"latestTime":"09:28 EST","volume":4182,"amount":402938.08374000003,"timestamp":1765549680034},"postHourTrading":{"tag":"盘后","latestPrice":98.58,"preClose":98.58,"latestTime":"19:23 EST","volume":4184,"amount":412458.77,"timestamp":1765585386013},"volumeRatio":1.0948276942511328,"impliedVol":0.8182,"impliedVolPercentile":0.9321},"requestUrl":"/m/hq/s/PVLA/tweets","defaultTab":"tweets","newsList":[{"id":"2589920378","title":"Palvella Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $167","url":"https://stock-news.laohu8.com/highlight/detail?id=2589920378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589920378?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:56","pubTimestamp":1764939364,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0Q9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2589892118","title":"BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892118","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892118?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:46","pubTimestamp":1764938809,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. (PVLA) has an average rating of Buy and mean price target of $143.07, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"gpt_icon":0},{"id":"2589313208","title":"Palvella Therapeutics Initiated at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589313208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589313208?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:03","pubTimestamp":1764871380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 13:03 ET (18:03 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2585460755","title":"Palvella Therapeutics price target raised to $145 from $87 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460755","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585460755?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:15","pubTimestamp":1763993717,"startTime":"0","endTime":"0","summary":"Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $145 from $87 and keeps a Buy rating on the shares. Despite the “tremendou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-145-from-87-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-145-from-87-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","SF"],"gpt_icon":0},{"id":"2585614724","title":"Stifel Nicolaus Keeps Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585614724","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585614724?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:17","pubTimestamp":1763986634,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Palvella Therapeutics today and set a price target of $145.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","SF"],"gpt_icon":0},{"id":"2584924514","title":"Palvella Therapeutics Shares Gain 11.2% After Raymond James Upgrades to 'Strong Buy' From 'Outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924514?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:26","pubTimestamp":1763573214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV1KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2584210269","title":"Palvella Therapeutics Reports Third Quarter 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584210269","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584210269?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:20","pubTimestamp":1763572830,"startTime":"0","endTime":"0","summary":"Nov 11 (Reuters) - Palvella Therapeutics Inc ::*PALVELLA THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE*PALVELLA THERAPEUTICS INC:  Q3 EPS $-1.03  ((Reuters In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6NCxkK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2584949946","title":"Palvella Therapeutics Raised to Strong Buy From Outperform by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949946?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:57","pubTimestamp":1763557020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 07:57 ET (12:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","RJF"],"gpt_icon":0},{"id":"2584457809","title":"Palvella Therapeutics Inc : Raymond James Raises to Strong Buy From Outperform; Raises Target Price to $143 From $92","url":"https://stock-news.laohu8.com/highlight/detail?id=2584457809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584457809?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:11","pubTimestamp":1763554308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2584945575","title":"Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2584945575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584945575?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:45","pubTimestamp":1763552709,"startTime":"0","endTime":"0","summary":"Raymond James upgraded Palvella Therapeutics (PVLA) to Strong Buy from Outperform with a price target of $143, up from $92. After further review of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-upgraded-to-strong-buy-from-outperform-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-upgraded-to-strong-buy-from-outperform-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","RJF"],"gpt_icon":0},{"id":"2583655679","title":"Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583655679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583655679?lang=en_us&edition=fundamental","pubTime":"2025-11-15 23:35","pubTimestamp":1763220927,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Palvella Therapeutics today and set a price target of $130.00. Slutsky covers the He...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-gets-a-buy-from-lifesci-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-gets-a-buy-from-lifesci-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2583596539","title":"Palvella Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583596539","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583596539?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:15","pubTimestamp":1763043300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 09:15 ET (14:15 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2583642055","title":"Palvella Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583642055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583642055?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:57","pubTimestamp":1763035056,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Palvella Therapeutics, with a price target of $148.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-strategic-advancements-and-promising-pipeline-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-strategic-advancements-and-promising-pipeline-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2583564203","title":"Palvella Therapeutics price target raised to $148 from $90 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2583564203","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583564203?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:55","pubTimestamp":1763034945,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $148 from $90 and keeps a Buy rating on the shares. The firm said 3Q25 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-148-from-90-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-148-from-90-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2583532619","title":"Chardan Capital Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583532619","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583532619?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:55","pubTimestamp":1763009717,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Geulah Livshits maintained a Buy rating on Palvella Therapeutics yesterday and set a price target of $110.00. Livshits cove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"1106472248","title":"Stock Track | Palvella Therapeutics Soars 5% as Raymond James Raises Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1106472248","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106472248?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:06","pubTimestamp":1762974377,"startTime":"0","endTime":"0","summary":"Shares of Palvella Therapeutics (PVLA) are soaring 5.04% in intraday trading on Wednesday, following a positive adjustment in analyst outlook. The biotech company's stock has caught investors'...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PVLA"],"gpt_icon":0},{"id":"2582345815","title":"Palvella Therapeutics Expands Rare Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2582345815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582345815?lang=en_us&edition=fundamental","pubTime":"2025-11-12 12:13","pubTimestamp":1762920839,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. ( ($PVLA) ) has released its Q3 earnings. Here is a breakdown of the information Palvella Therapeutics, Inc. presented ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-expands-rare-disease-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-expands-rare-disease-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2582132193","title":"Palvella Therapeutics: Strong Financial Position and Promising Clinical Trials Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582132193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582132193?lang=en_us&edition=fundamental","pubTime":"2025-11-12 06:55","pubTimestamp":1762901719,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Palvella Therapeutics, with a price target of $97.00. Ritu Baral ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-strong-financial-position-and-promising-clinical-trials-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/palvella-therapeutics-strong-financial-position-and-promising-clinical-trials-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2582390415","title":"Promising Clinical Developments and Stable Financials Drive Buy Rating for Palvella Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2582390415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582390415?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:35","pubTimestamp":1762896923,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with a price target of $130.00. Sam ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-stable-financials-drive-buy-rating-for-palvella-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-stable-financials-drive-buy-rating-for-palvella-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2582939983","title":"Palvella Therapeutics price target raised to $120 from $100 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582939983","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582939983?lang=en_us&edition=fundamental","pubTime":"2025-11-12 01:40","pubTimestamp":1762882818,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $120 from $100 and keeps an Outperform rating on the shares. Publishe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-120-from-100-at-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-120-from-100-at-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","PVLA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":0.209},{"period":"3month","weight":0.7343},{"period":"6month","weight":2.9353},{"period":"1year","weight":5.1116},{"period":"ytd","weight":7.215}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.102904},{"month":2,"riseRate":0.5,"avgChangeRate":0.02179},{"month":3,"riseRate":0.5,"avgChangeRate":0.012293},{"month":4,"riseRate":0.2,"avgChangeRate":-0.082116},{"month":5,"riseRate":0.5,"avgChangeRate":0.168212},{"month":6,"riseRate":0.4,"avgChangeRate":-0.088952},{"month":7,"riseRate":0.727273,"avgChangeRate":0.169693},{"month":8,"riseRate":0.636364,"avgChangeRate":0.117993},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.090465},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.050324},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.056685}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}